Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis.

ABSTRACT:

Objective

To systematically evaluate the efficacy and safety of alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer.

Methods

Studies about the efficacy of alectinib versus crizotinib in the treatment of ALK-positive non-small cell lung cancer were searched in PubMed, Scopus, Embase and the Cocharane Library from inception to February 15, 2020. Two reviewers independently screened these studies, extracted the data, assessed the risk of bias in the included studies by using the Cochrane risk assessment tool, and then used review manager 5.3 software for meta-analysis.

Results

Three studies comprising a total of 697 patients with ALK-positive non-small cell lung cancer were included, 38

SUBMITTER: Tang H 

PROVIDER: S-EPMC8206528 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature